NCT05007678View on ClinicalTrials.gov

Targeting de Novo Pyrimidine Biosynthesis by Leflunomide for the Treatment of COVID-19 Virus Disease

PHASE3CompletedINTERVENTIONAL

Enrollment

178

Participants

Timeline

Start Date

September 16, 2020

Primary Completion Date

July 1, 2022

Study Completion Date

July 1, 2022

Conditions

COVID-19

Interventions

DRUG

leflunomide

leflunomide administered orally; daily loading dose of 100mg for 3 days, followed by a daily maintenance dose 10-20mg daily, to a total course of 10 days

Trial Locations (1)

KT16 0PZ

Ashford and St Peters Hospital NHS Foundation Trust, Chertsey

All Listed Sponsors

lead

Ashford and St. Peter's Hospitals NHS Trust

OTHER

NCT05007678 - Targeting de Novo Pyrimidine Biosynthesis by Leflunomide for the Treatment of COVID-19 Virus Disease | Biotech Hunter | Biotech Hunter